# Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.

> **NCT07569653** · PHASE4 · RECRUITING · sponsor: **WeiShi** · enrollment: 120 (estimated)

## Conditions studied

- Cytomegalovirus Infections
- Cytomegalovirus Disease
- Hematopoietic Stem Cell Transplantation
- Graft vs Host Disease

## Interventions

- **DRUG:** CMV-Specific T-cell Guided Letermovir Discontinuation
- **DRUG:** Standard Letermovir Prophylaxis

## Key facts

- **NCT ID:** NCT07569653
- **Lead sponsor:** WeiShi
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-30
- **Primary completion:** 2027-10
- **Final completion:** 2027-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07569653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07569653, "Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07569653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*